Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Multi-drug resistance (MDR) in cancer cells, either intrinsic or acquired through various
mechanisms, significantly hinders the therapeutic efficacy of drugs. Typically, the reduced …

Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …

Progress in defining genomic fitness landscapes in cancer, especially those defined by copy
number alterations (CNAs), has been impeded by lack of time-series single-cell sampling of …

Cancer patient classification using predictive biomarkers for anti-cancer drug responses is
essential for improving therapeutic outcomes. However, current machine-learning-based …

Adaptive therapy is a dynamic cancer treatment protocol that updates (or 'adapts') treatment
decisions in anticipation of evolving tumor dynamics. This broad term encompasses many …

Recent progress in understanding the molecular basis of cellular processes, identification of
promising therapeutic targets and evolution of the regulatory landscape makes this an …

Lineage-tracing methods have enabled characterization of clonal dynamics in complex
populations, but generally lack the ability to integrate genomic, epigenomic and …

Eg5, the product of Kif11 gene, also known as kinesin spindle protein, is a motor protein
involved in the proper establishment of a bipolar mitotic spindle. Eg5 is one of the 45 …